Taken together, we believe our results for TMPRSS5 and NfL support a complementary biomarker strategy in CMT1A in which TMPRSS5 can serve as a novel potential biomarker for myelinating Schwann cells, along with assessments of NfL as a marker for axonal degeneration. Here, TMPRSS5 is linked to Charcot-Marie-Tooth disease type 1A.